Cutler Group’s Zevra Therapeutics ZVRA Stock Holding History

Cutler Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,500	Closed	-$1K	–	5379
2022 Q3	$1K	Hold	7,500	–	–	﹤0.01%	4751
2022 Q2	$2K	Sell	7,500 -9,500	-56%	-$43.3K	﹤0.01%	4408
2022 Q1	$3K	Buy	17,000 +8,000	+89%	+$50.9K	﹤0.01%	4556
2021 Q4	$13K	Sell	9,000 -21,400	-70%	-$191K	﹤0.01%	3506
2021 Q3	$67K	Sell	30,400 -5,700	-16%	-$57.5K	﹤0.01%	2269
2021 Q2	$149K	Buy	36,100 +20,000	+124%	+$215K	0.01%	1555
2021 Q1	$15K	Buy	+16,100	New	+$141K	﹤0.01%	3470

Other funds holding ZVRA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return

Cutler Group's ZVRA Position: Q1 2023 in Review

Cutler Group sold out of Zevra Therapeutics (ZVRA) in Q1 2023, closing a stake of 679 shares — an estimated $3K sold.

Cutler Group first reported a position in ZVRA in Q2 2016 and held it in 10 quarters. The position peaked at $119K in Q1 2021. 60 funds tracked by Wall St. Rank hold ZVRA as of Q1 2023.

Cutler Group reported no remaining Zevra Therapeutics position as of Q1 2023 after selling out during the quarter.
Cutler Group sold 679 Zevra Therapeutics shares in Q1 2023, an estimated $3K.
Cutler Group first reported a position in Zevra Therapeutics in Q2 2016 and held it in 10 quarters.
Cutler Group's Zevra Therapeutics position peaked at $119K in Q1 2021.
60 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.